The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers
Open accessAbstract
Purpose: Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) have been associated with the aggressive nature of head and neck cancers (HNCs). These tumours grow diffusely, leading to extremely challenging differentiation between tumour and healthy tissue. This analysis aims to introduce a novel approach of tumour detection, contouring and targeted radiotherapy of HNCs using visualisation of CAFs: PET-CT with 68 Ga-radiolabeled inhibitors of FAP (FAPI). Methods: FAPI PET-CT was performed without complications prior to radiotherapy in addition to contrast enhanced CT (CE-CT) and MRI on 14 patients with HNC. First, for tissue biodistribution analysis, volumes of interest were defined to quantify SUV mean and SUV max in tumour and healthy parenchyma. Secondly, using four thresholds of three-, five-, seven- and tenfold increase of FAPI enhancement in the tumour as compared with normal tissue, four different gross tumour volumes (FAPI-GTV) were created automatically. These were compared with GTVs created conventionally with CE-CT and MRI (CT-GTV). Results: The biodistribution analysis revealed high FAPI avidity within tumorous lesions (e.g. primary tumours, SUV max 14.62 ± 4.44; SUV mean 7.41 ± 2.39). In contrast, low background uptake was measured in healthy tissues of the head and neck region (e.g. salivary glands: SUV max 1.76 ± 0.31; SUV mean 1.23 ± 0.28). Considering radiation planning, CT-GTV was of 27.3 ml, whereas contouring with FAPI resulted in significantly different GTVs of 67.7 ml (FAPI × 3, p = 0.0134), 22.1 ml (FAPI × 5, p = 0.0419), 7.6 ml (FAPI × 7, p = 0.0001) and 2.3 ml (FAPI × 10, p = 0.0001). Taking these significant disparities between the GTVs into consideration, we merged FAPI-GTVs with CT-GTVs. This resulted in median volumes, that were, as compared to CT-GTVs, significantly larger with FAPI × 3 (54.7 ml, + 200.5% relative increase, p = 0.0005) and FAPI × 5 (15.0 ml, + 54.9%, p = 0.0122). Furthermore, FAPI-GTVs were not covered by CE-CT-based planning target volumes (CT-PTVs) in several cases. Conclusion: We present first evidence of diagnostic and therapeutic potential of FAPI ligands in head and neck cancer. Larger studies with histopathological correlation are required to validate our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860 · cited 2×
“Hence, directly targeting CAFs which are made visible by FAPI-PET, with a radiation boost emerges as a new perspective of treatment not only because the cancer is more accurately targeted but also because the precise elimination of CAFs can sensitise the entire tumour to radiation, chemoimmunotherapy and the body’s ow…”
BackgroundCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Sandberg, T. P., Stuart, M. P. M. E., Oosting, J., Tollenaar, R. A. E. M., Sier, C. F. M., & Mesker, W. E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5462-2 · Cited by 135
Cited by
The Latest Developments in Imaging of Fibroblast Activation Protein
Altmann, A., Haberkorn, U., & Siveke, J. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244806 · Cited by 257
Self-citationRole of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)
Naser, R., Fakhoury, I., El‑Fouani, A., Abi‑Habib, R., & El‑Sibai, M. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5471 · Cited by 61
Metadata
- Authors
- Syed, M., Flechsig, P., Liermann, J., Windisch, P., Staudinger, F., Akbaba, S., Koerber, S. A., Freudlsperger, C., Plinkert, P. K., Debus, J., Giesel, F., Haberkorn, U., & Adeberg, S.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2020-05-23
- Volume
- 47
- Issue
- 12
- Pages
- 2836-2845
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W3026198184
- Cited by
- 164
- References
- 4
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. https://app.cochat.ai/papers/10.1007/s00259-020-04859-y
- The paper
- Syed, M., Flechsig, P., Liermann, J., Windisch, P., Staudinger, F., Akbaba, S., Koerber, S. A., Freudlsperger, C., Plinkert, P. K., Debus, J., Giesel, F., Haberkorn, U., & Adeberg, S. (2020). Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-020-04859-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.